The range of glucose-lowering drugs available to physicians has expanded greatly since the early landmark studies in this field. New regulations have also changed the way cardiovascular risk is factored into contemporary trial design. With these changes in mind, this module looks at the cardiovascular aspects of the outcomes from trials of the newer diabetes therapies.
By the end of this module, you will be able to:
✓ Explain the USA’s Food and Drug Administration’s (FDA) guidance on cardiovascular safety
✓ Summarise the main cardiovascular outcome data for clinical trials of DPP-4 inhibitors, SGLT-2 inhibitors and GLP-1 receptor agonists
✓ Discuss how the cardiovascular aspects of the outcomes from trials of the newer diabetes therapies will influence your clinical practice
This module includes self-marked assessments, such as knowledge checks and/or case studies, as well as a marked final assessment, which you can attempt up to five times. To complete the module, you must review all chapters, pass the final assessment (80% pass mark), and fill in our feedback form.